CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 160 enrolled
Drug / intervention
Tigertriever revascularization devicedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03474549
NCT03474549N/ACompleted

Treatment With Intent to Generate Endovascular Reperfusion

Rapid Medical·interventional·Posted Mar 22, 2018·Updated May 8, 2024

In Brief

A clinical study evaluating Tigertriever revascularization device for Ischemic Stroke. Completed, enrolled 160 participants across 17 sites in 2 countries.

Detailed Summary

Tigertriever is a CE marked mechanical revascularization device indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for IV t-PA or who fail IV t-PA therapy are candidates for treatment. The objective of the TIGER Study is to evaluate the safety and effectiveness of the Tigertriever device in restoring blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke due to a large vessel occlusion (LVO). This study is designed to support substantial equivalence to approved and marketed products such as the Solitaire or Trevo Retriever.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIschemic Stroke
CountriesIsrael, United States
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedMar 22, 2018
Enrollment StartMay 9, 2018
Primary CompletionApr 15, 2020
Study CompletionJun 30, 2020
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 8.3 years ago

Interventions

Tigertriever revascularization devicedevice

Mechanical Thrombectomy